Spur Capital Partners logo

Spur Capital Partners

North America, Oklahoma, United States, Bartlesville

Description

Spur Capital Partners focuses on venture partnerships that invest primarily in early-stage U.S. companies.

Investor Profile

Spur Capital Partners has backed more than 2 startups, with 1 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series E, Series F rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.

Stage Focus

  • Series E (50%)
  • Series F (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Spur Capital Partners frequently co-invest with?

UCB Ventures
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 2
CA
North America, Massachusetts, United States, Boston
Co-Investments: 2
EC
North America, New York, United States, New York
Co-Investments: 2
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 2
UI
North America, California, United States, Oakland
Co-Investments: 2
BF
North America, California, United States, Berkeley
Co-Investments: 2
Viking Global Investors
North America, Connecticut, United States, Stamford
Co-Investments: 2
LYFE Capital
Asia, Central Region, Singapore, Singapore
Co-Investments: 2
Schroders Capital
Europe, England, United Kingdom, London
Co-Investments: 2
The Column Group
North America, California, United States, San Francisco
Co-Investments: 2

What are some of recent deals done by Spur Capital Partners?

Neurona Therapeutics

San Francisco, California, United States

Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.

BiotechnologyHealth CareTherapeutics
Series FApr 3, 2025
Amount Raised: $102,000,000
Neurona Therapeutics

San Francisco, California, United States

Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.

BiotechnologyHealth CareTherapeutics
Series EFeb 8, 2024
Amount Raised: $120,000,000